NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.

Journal Article (Journal Article)

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.

Full Text

Duke Authors

Cited Authors

  • Wierda, WG; Brown, J; Abramson, JS; Awan, F; Bilgrami, SF; Bociek, G; Brander, D; Chanan-Khan, AA; Coutre, SE; Davis, RS; Eradat, H; Fletcher, CD; Gaballa, S; Ghobadi, A; Hamid, MS; Hernandez-Ilizaliturri, F; Hill, B; Kaesberg, P; Kamdar, M; Kaplan, LD; Khan, N; Kipps, TJ; Ma, S; Mato, A; Mosse, C; Schuster, S; Siddiqi, T; Stephens, DM; Ujjani, C; Wagner-Johnston, N; Woyach, JA; Ye, JC; Dwyer, MA; Sundar, H

Published Date

  • June 2022

Published In

Volume / Issue

  • 20 / 6

Start / End Page

  • 622 - 634

PubMed ID

  • 35714675

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2022.0031


  • eng

Conference Location

  • United States